Objective : To determine the efficacy of oral prednisolone among children with acute bronchiolitis who have associated family history of atopy.
Introduction
Bronchiolitis is a major public health problem throughout the world 1 . In Bangladesh a country wide survey on 5157 under 5 sick children in 42 hospitals showed that respiratory problems comprised of about 67% and out of that bronchiolitis is the most common lower respiratory illnesses among under 5 children. 2 But treatment is only supportive with unpredictable outcome and high morbidity.
Around 80-90% of Bronchiolitis are due to RSV. 3 An Ig-E mediated immune response is noted in most of the cases of RSV bronchiolitis, especially among atopy-prone children e.g. those with positive H/O atopy among 1 st degree relatives. [1] [2] [3] [4] [5] [6] As Systemic steroids are effective option of treatment for atopic disorders, assuming that bronchiolitis if more severe and refractory to conventional treatment in atopyprone children is due to possible underlying immune mechanism. Therefore, it is hypothesized that children with bronchiolitis and family history of atopy may be benefited from systemic steroid in addition to other supportive measures.
Materials & Methods
This randomized double blind placebo controlled trial was conducted in Department of Paediatrics in Dhaka Medical College Hospital (DMCH), Bangladesh from July' 2 0 08 to June'2010. Ethical clearance was obtained from the ethical review committee of DMCH to conduct the research work. Sample size for this study was calculated by stata software. Total 60 children between 1 month-2 years of age, both male and female, who were hospitalized with bronchiolitis and had Family History of atopy were enrolled in this study. Informed written consent was t a ken f r om the parents or legal guardian for enrolment of their child in this study. In this study population bronchiolitis was diagnosed clinically by presence of cough, breathing difficulty, chest indrawing and ronchi on auscultation following a viral upper respiratory catarrh. 7 Family h i story of atopy was defined by presence of atopy of any form (asthma, allergic rhinitis, allergic conjunctivitis, eczema) in any of the 1 st degree relatives (father, mother, sister, brother). Children having recurrent attacks of wheeze with associated respiratory disorders e.g. pneumonia, pneumothorax, laryngo/ tracheomalacia, associated co-morbidities e.g. Severe Acute Malnutrition (SAM), heart failure, Down syndrome or previous history of treatment with prednisolone and/or bronchodilator were excluded from the study. After enrollment all patients were thoroughly assessed clinically, a base line CXR and complete blood count were done. The patients were allocated either in Prednisolone or in Placebo groups randomly by lottery, i.e. the parents or accompanying guardian picked up a sealed encoded envelop from a box of eight. Each encoded envelop contained 15 small packets of powdered prednisolone or placebo, each weighing 5 mg. The code was given by the guide and code numbers were recorded in a preformed questionnaire. Both the researcher a n d the parents remained blind about the allocation. Out of 60 children 30 cases received prednisolone (2mg/kg/day) and 30 cases received same amount of placebo made of flour orally at 8 hours interval for 3 c onsecutive days. In addition, both groups received Oxygen, nutritional support and nebulized salbutamol & ipratropium. During study, patients were monitored twice daily for clinical response to therapy by modified Respiratory Distress Assessment Instrument score (mRDAI) [annex 1] for 3 consecutive days. Duration of Oxygen therapy and length of hospital stay were also documented. Descriptive statistical analysis was done by using frequency tabulation, mean and standard deviation. Chi-square test for qualitative variables and student t-test for continuous variables were applied to determine statistical significance. Statistical significance was set at p value <0.05 at 95% confidence interval.
Modified Respiratory Distress Assessment Instrument (mRDAI) Score
Result 60 children were enrolled in this study and were treated either with prednisolone or placebo by lottery method, 30 patients in each group.
The baseline characteristics among the study (prednisolone) and control (placebo) group including age, sex, clinical presentation (fever, feeding difficulty, SpO2) and family history of atopy were statistically comparable as shown in Table I . Mean age of affection of the patients with bronchiolitis in this study was 3.68 months (±1.29SD) and 3.52 months (±1.1SD) in prednisolone and placebo group respectively. Though male are predominantly affected in both study and control group in this study, 53.3% and 66.7% respectively, there is no significant statistical difference in baseline characteristics among the groups. 
Discussion
Acute bronchiolitis is the leading cause of hospitalization in children below 2 years of age. In this study male are predominantly affected in both groups, control groups with 53.3% and 66.7% respectively, however male-female distribution is statistically comparable in both the groups. Mean age of the patients affected with bronchiolitis in this series was 3.68 months (±1.29SD) in prednisolone group and 3.52 months (±1.1SD) in placebo group. The clinical presentations of the patient in the study include cough, fast breathing, respiratory distress, chest indrawing and wheeze which were quite similar to what was observed in the study by Ahmed A. 7 In this study to determine treatment response patients were evaluated by modified Respiratory Distress Assessment Instrument score (mRDAI). Respiratory rate was found to decrease significantly (p<0.01) in prednisolone group within 2 days. Ahmed A also observed similar improvement in fast breathing (p<0.05) within 72 hours of treatment with oral prednisolone compared to placebo in his study. 8 Use of accessory muscle which is a very good predictor for respiratory distress in children also showed significant improvement (p<0.01) within 2 days of oral prednisolone therapy in this study which observation is comparable to what was found in the study by Klassen TP et al. 9 In this study, duration of oxygen requirement was significantly lower in prednisolone group (13.7hrs) compared to placebo group(24.1hrs) and this difference was significant (p<0.05) This finding is consistent with the observation of Klassen TP et al 9 There was also marked decline in duration of hospital stay (3.3 vs 4.6days; p<.01) in prednisolone treated group. Similar shorter hospital stay was seen in another study by C sonka P et al. 10 Khalid Alansari, et al. also found shortened time for discharge in bronchiolitic patients with eczema or a family history of asthma in a first-degree relative after treating with oral corticosteroid (Dexamethasone) in their study which may indicate that corticosteroid plays a positive role in treating atopy-prone bronchiolitis patient. 11 In other study by von Woensen, et al. it was found that duration of hospital stay in mechanically ventilated bronchiolitis cases was shorter who were treated with prenisolone compared to those who didn't require mechanical ventilation but treated with prednisolone, the symptom score decreased significantly faster which finding is compatible to our study findings. 12
Conclusion
Three days of oral prednisolone therapy along with supportive measures was found to be significantly useful among children with acute bronchiolitis having family history of atopy in terms of clinical recovery, oxygen requirement and duration of hospital stay.
Recommendation
Further multicenter research with larger sample size is recommended to provide information about benefits of steroids in acute bronchiolitis and also its role in atopy-prone children.
